Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson’s disease

  • A. Y. Deutch
Part of the Journal of Neural Transmission. Supplementa book series (NEURALTRANS, volume 70)


Striatal dopamine loss in Parkinson’s Disease (PD) sets into play a variety of compensatory responses to help counter dopamine depletion. Most of these changes involve surviving dopamine neurons, but there are also changes in striatal medium spiny neurons (MSNs), which are the major target of dopamine axons. Among these changes are decreases in MSN dendritic length and spine density, which may dampen excessive corticostriatal glutamatergic drive onto MSNs that occurs secondary to dopamine loss. An increasing knowledge of dendritic changes in PD suggests strategies for tracking progressive worsening of symptoms and is opening new ideas on novel therapeutic strategies for PD.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arbuthnott GW, Ingham CA, Wickens JR (2000) Dopamine and synaptic plasticity in the neostriatum. J Anat 196: 587–596PubMedCrossRefGoogle Scholar
  2. Bolam JP (1984) Synapses of identified neurons in the neostriatum. Ciba Found Symp 107: 30–47PubMedGoogle Scholar
  3. Brown AM, Deutch AY, Colbran RJ (2005) Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism. Eur J Neurosci 22: 247–256PubMedCrossRefGoogle Scholar
  4. Day M, Wang Z, Deng J, An X, Ingham CA, Schering AF, Wokosin D, Ilijic E, Sun Z, Sampson AR, Mugnaini E, Deutch AY, Sesack S, Arbuthnott G, Surmeier DJ (2006) Calcium channel dependent elimination of glutamatergic synapses on striatopallidal neurons in Parkinson’s disease models. Nature Neurosci 9: 251–259PubMedCrossRefGoogle Scholar
  5. Dunah AW, Wang Y, Yasuda RP, Kameyama K, Huganir RL, Wolfe BB, Standaert DG (2000) Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-Daspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson’s disease. Mol Pharmacol 57: 342–352PubMedGoogle Scholar
  6. Hernandez-Lopez S, Tkatch T, Perez-Garci E, Galarraga E, Bargas J, Hamm H, Surmeier DJ (2000) D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. J Neurosci 20: 8987–8995PubMedGoogle Scholar
  7. Kelley JJ, Gao XM, Tamminga CA, Roberts RC (1997) The effect of chronic haloperidol treatment on dendritic spines in the rat striatum. Exp Neurol 146: 471–478PubMedCrossRefGoogle Scholar
  8. Segal M (1995) Dendritic spines for neuroprotection: a hypothesis. Trends Neurosci 18: 468–471PubMedCrossRefGoogle Scholar
  9. Stephens B, Mueller AJ, Shering AF, Hood SH, Taggart P, Arbuthnott GW, Bell JE, Kilford L, Kingsbury AE, Daniel SE, Ingham CA (2005) Evidence of a breakdown of corticostriatal connections in Parkinson’s disease. Neurosci 132: 741–754CrossRefGoogle Scholar
  10. Zaja-Milatovic S, Milatovic D, Schantz AM, Zhang J, Montine KS, Samii A, Deutch AY, Montine TJ (2005) Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 64: 545–547PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • A. Y. Deutch
    • 1
  1. 1.Departments of Psychiatry and PharmacologyVanderbilt University Medical Center, Psychiatric Hospital at VanderbiltNashvilleUSA

Personalised recommendations